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Abstract 
Objectives: There are many antipsychotic medications that have been shown to be associated with the 
prolongation of the rate-corrected QT (QTc) interval on the electrocardiogram (ECG). Studies have shown 
that QTc prolongation is associated with increased risk of arrhythmias and sudden cardiac death. This study 
aims to identify and study the risk profile of patients on high-dose antipsychotic and to examine the prevalence 
of rate and rhythm abnormalities, in particular, QTc prolongation. We hope that this study could throw a 
light on current practice patterns and also could potentially guide us towards safe practice in the future. 
Methods: We recruited 37 adult outpatients who are on high-dose antipsychotic from the 3 outpatient clinics of 
the Institute of Mental Health in Singapore. Baseline characteristics risk profiling was performed to identify 
their pre-existing risk, including checks on Calcium, Potassium and Magnesium levels to rule out confounders. 
12 lead ECG was done and reviewed manually by our resident physician. Results: It showed that rate 
abnormality was detected in 8 patients (22%) and QTc interval prolongation was detected in nearly 12 
patients (32.4%) but of those only 3 patients had significantly prolonged QT interval needing the primary 
treating team to review their psychopharmacology regime. Conclusion: QTc Prolongation was positively 
linked with a number of cardiovascular risk factors.  
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Introduction 
The association between antipsychotics and 
cardiovascular events has been well known, in 
particular, the prolongation of the rate-corrected QT 
(QTc) interval, which is associated with potentially 
life-threatening cardiac arrhythmias, especially 
Torsades de Pointes (TdP). Harmful effects of 
antipsychotic were proven at therapeutic levels in a 
dose-dependent way as well as in patients with 
comorbid cardiovascular disease [1,2]. Newer 
atypical antipsychotics are thought to be relatively 
safe compared to typical medication with the 
exception of established risk with sertindole, 
ziprasidone, and clozapine. The association between 
prolongation of QTc interval and sudden cardiac 
death has been confirmed in a meta-analysis of 23 
observational studies, showing a dose-related effect 
of antipsychotic medications on QTc interval and 
subsequent mortality [3].  
In Singapore, a local study by Chong and colleagues 
reported that of the 163 in patients with 
schizophrenia who were prescribed any psychotropic 
medications, 110 patients (67.5%) received more 
than one medication, and 11 (6.7%) of them had a 
prolonged QTc interval [4]. This study however only 
looked at typical antipsychotics and the practice of 
use of typical versus atypical antipsychotics has since 
then changed dramatically. A more recent study by 
Ng and colleagues conducted in Singapore reported 
that of the 107 patients with the diagnosis of 
schizophrenia who were on antipsychotic 
medication, there were 31 patients (29.0%) who had 
ECG during their hospitalization [5]. Of this group, 
20.6% were thought to be on a high dose and 62.6% 
were on combination antipsychotics. Of the 95 
patients who had moderate-to-high risk of 
developing QTc prolongation, only 29 of them 
received ECG. Of the 31 patients who had ECG, 10 
of them (32.3%) had QTc prolongation, with 2 
patients had a QTc interval of over 500 ms. In this 
study, machine calculated QTcB was used and there 
was no manual reading of the ECGs. It did not 
differentiate patients being on typical, atypical or 
combinations antipsychotics. A few other studies 
also had reported inadequate ECG monitoring in 
patients on antipsychotic medications [6,7]. Although 
several publications have highlighted the importance 
of ECG monitoring in patients receiving 
antipsychotic medications, there is no clear 
consensus detailing precisely how and when this 
should be done.  
High dose antipsychotic and antipsychotic 
polypharmacy is not uncommon in clinical practice 
despite scarce evidence for antipsychotic 
polypharmacy, concerns about increased adverse 
events and healthcare costs. Despite this, 
 
  
antipsychotic polypharmacy continues to prevail. 
Risks associated with high doses and combination of 
antipsychotics are not that well studied.  
This study aims to identify and study the risk profile 
of patients on high-dose antipsychotic and to study 
the prevalence of rate abnormality and QTc 
prolongation in these patients. We define high-dose 
antipsychotic either as monotherapy, with the 
individual antipsychotic above the maximum dosage 
recommended by the British National Formulary, or 
as polypharmacy, with a total antipsychotic daily 
dosage equivalent to 1 gram or more of 
chlorpromazine [8,9]. A normal QTc interval is 
generally defined as <450 ms for men and <460 ms 
for women [10]. The above reference point was used 
in Study by Ng et al., Some studies quoted 430-450 
ms as a borderline rise for men and 450-470 ms as a 
borderline rise for women [11]. QTc interval over 
500 ms is generally considered to be a major risk 
factor for cardiac arrhythmias [12]. Risk factors for 
QTc prolongation include increased age, female 
gender, congenital long QT syndrome, 
cardiovascular risk factors and disease, other medical 
conditions (commonly electrolyte abnormalities), 
psychotropic and non-psychotropic medications [13]. 
Prolonged QTc is considered a surrogate marker of 
polymorphic ventricular tachyarrhythmias such as 
TdP [14]. QTc prolongation is not an invariable 
precursor for TdP [15]. Risk is thought to be high 
when a person has a combination of factors as such 
genetic predisposition and also drugs that prolong 
QTc on top of that. This study has been approved by 
the IMH Clinical Research Committee and National 
Healthcare Group DSRB and supported by their seed 
funding.  
We hope that the findings of this study could help us 
better understand the risk profile of patients needing 
high dose antipsychotics, the current level of ECG 
monitoring in such patient groups and the association 
between high-dose antipsychotic and QTc 
prolongation. We also hope that this study would 
remind clinicians to be more vigilant and could 
potentially guide clinicians towards safe practice in 
this group of patients. 
Method 
We included patients aged 21-65 years with any 
psychiatric diagnosis from the 3 outpatient clinics of 
the IMH of Singapore from June 2016 and Dec 2017. 
They are on high-dose antipsychotic that was defined 
either as 1) monotherapy, with the individual 
antipsychotic above the maximum dosage 
recommended by the Institute of Mental Health 
Pharmacy Department, references used include 
British National Formulary, MICROMEDEX 
(DRUGDEX) Healthcare Series, American Hospital 
Formulary System, Manufacturers Product 
Information and UpToDate, or 2) as polypharmacy, 
with a total antipsychotic daily dosage equivalent to 
1 gram or more of chlorpromazine -CPZ). Informed 
consent was obtained. Exclusion criteria include 
intellectual disability, female patients who are 
pregnant or breastfeeding, patients taking drugs that 
are known to cause significant impact on QT 
prolongation (antiarrhythmic Class I and Class III 
drugs, imidazole antifungal agents, antibiotics of 
macrolide derivatives and fluoroquinolone group, 
certain non-sedating antihistamines such as 
terfenadine and astemizole) and tricyclic 
antidepressants. Pharmacists in the study team 
identified patients who are on high-dose 
antipsychotic via the Online Analytical Processing 
system and coordinated patients’ study visits. They 
then tagged the recruited patients and those who 
refused consent to prevent duplication. The initial 
aim was to recruit a total of 80 patients from our 3 
outpatient clinics.  
Clinicians obtained the following information from 
the consenting patients and their electronic medical 
records, such as demography (age, race, gender), 
psychiatric diagnosis, cardiovascular risk 
factor/disease (smoking, lack of exercise, obesity, 
hyperlipidaemia, hypertension and diabetes mellitus 
and ischaemic heart disease, valvular heart disease 
and arrhythmia), family history of cardiovascular risk 
factor/disease or sudden death, other medical history 
(renal/liver dysfunction, hypothyroidism), 
antipsychotics details (name, dosage per day and 
chlorpromazine equivalent dose) other psychotropic 
and non-psychotropic medications, any ECG done in 
the past 12 months and the findings of such if it was 
done. Subsequently, the clinicians ordered an ECG 
and blood tests (potassium, calcium and magnesium 
levels) to reduce the confounding. Participants were 
given S$30 as an inconvenience fee. The ECG and 
blood results were uploaded onto their electronic 
documents for patients’ primary physician to have 
access. All ECGs were done from Philip ECG 
machine (models 1. TC50 and Model 2. 
US90821237) throughout the study [16]. Resident 
physician (RI) manually read all the ECGs. 
Parameters such as Rate, PR interval, QRS duration 
and axis, QT interval and QTc, ST segment and T 
wave are studied in addition to physician’s overall 
comment on the ECGs. Manual reading of QT done 
from lead II and compared with another best lead to 
double check QT calculations. Rate correction was 
done using Bazett’s Formula (QT/RR). Bazett’s 
formula is the most commonly used method to adjust 
for heart rate, unless there is severe Brady or 
tachyarrhythmias (below 60 and above 100Bpm) 
when Bazett’s method tends to give an erroneous 
reading.  
We also studied whether the frequency of rate and 
QTc interval abnormality was in anyway related to 
any other significant factors such as a number of 
cardiovascular risk factors (high risk was defined as 
the presence of 3 or more factors), having (3 or 
more) combination of antipsychotics and also very 
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high doses (up to CPZ 1500 mg equivalent vs more 
than CPZ 1500mgs equivalent).  
Statistical Analyses 
The statistical analysis was performed using 
Statistical Package for the Social Sciences (SPSS) 
version 16.0 [17]. Mean and standard deviations 
were calculated for continuous variables, and 
frequencies and percentages were calculated for 
categorical variables. Significant associations 
between two categorical variables were tested using 
Chi-square test and Fisher exact test if the expected 
value in each cell is greater than 5. All significance 
tests were performed using two-sided tests evaluated 
at the 0.05 level of significance  
Result 
Only 37 patients consented out of 113 who have 
fulfilled a high dose category. We feel that it is the 
blood test that had deterred patients from 
participating despite the inconvenience fee. Baseline 
characteristics and risk profiling of consented 
patients on high dose antipsychotics are shown in the 
given data (Table 1).  
Table 1. Baseline characteristics of patients on high dose antipsychotics. 
Socio-demography 
Gender Male 64.9%, Females 35.1% 
Race Chinese (73%), Malay (16.2%) and Indian (10.8%) 
Age Average 48 (Range 27-65) 
Diagnosis Schizophrenia 95%, Schizoaffective disorder 5% 
Cardio-vascular risk factors 
Smoking Yes (27%) 
Lack of exercise (regular >1 in a week) Yes (49% 
Obesity Yes (32.4%) 
Hyperlipidaemia Yes (62.2%) 
Hypertension Yes (37.8) 
Diabetes Mellitus Yes (29.7%) 
Past h/o Ischaemic HD Yes (0%) 
Past h/o Valvular HD Yes (0%) 
Past h/o Arrhythmia Yes (2.7%) 
Family h/o IHD  Yes (37.8%) 
Antipsychotics prescribing patterns 
Number of antipsychotics 2 (46%), 3 (46%), 4 (5.2%), 6 (2.7%) 
Dose of antipsychotics (CPZ equivalent) 
1000-1500 mgs (89.2%), 1500-2000 mgs (5.4%), 
>2000 mgs (5.4%) 
Type of antipsychotics 
Atypical and Typical combination (83.8%), 
Typicals only (10.8%) and Atypicals only (5.4%) 
Use of depot antipsychotics Yes (83.8%) 
Other psychotropic medication usage 
Mood stabilisers Yes (43%) 
  Lithium use (8%) 
Anticholinergics Yes (65%) 
Antihistamines Yes (24%) 
Benzodiazepine Yes (51.4%) 
Propranolol Yes (13.5%) 
SSRI antidepressants Yes (32.4%) 
Escitalopram  -3% 
Non-Psychotropic Medication Usage 
Antihypertensive Yes (27%) 
Anti-hyperglycaemic Yes (21.6%) 
Anti-hyperlipidaemic Yes (46%) 
Thyroid supplements Yes (3%) 
Others Yes (24.3%) 
Pre-study ECG monitoring (6-12months earlier) 
Baseline ECG done  Yes (24.3%) 
Presence of significant electrolyte abnormality  
Abnormal K/Ca/Mg No (0%) 
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Of the 37 patients who had their ECG done, 64.9% 
of them are males, 73% are Chinese ethnic origin 
with a mean age of 48 (ranged between 27 and 65) 
and almost all of them had the diagnosis of 
Schizophrenia except 2 cases of Schizoaffective 
disorders. Amongst the cardiovascular risk factors 
studied 62.2% had hyperlipidemia, followed by 
Hypertension (37.8%) and then Diabetes (29.7%). A 
significant proportion of cases also had a family 
history of Ischaemic Heart Diseases too (37.8%) and 
nearly half of them do not engage in regular exercise 
(49%) and nearly a third (27%) are smokers. Looking 
at their antipsychotic prescription patterns all of them 
had combination antipsychotics, the majority had 2 
and 3 antipsychotic combinations (46% each) whilst 
a small proportion were given a combination of 4 or 
more (8%). Amongst the use of antipsychotic, 
flupenthixol depot (57%) was the most commonly 
prescribed medication followed by oral risperidone 
(41%) and then quetiapine (35%). Oral haloperidol, 
chlorpromazine, and zuclopenthixol depot were 
prescribed in 22% of subjects each. The majority 
were given CPZ equivalent of between 1000 and 
1500 mgs (89.2%), 2 cases were given CPZ 
equivalent of between 1500 and 2000 mgs and 2 
cases were given CPZ equivalent dose over 2000 
mgs. To assess the impact of CPZ equivalent above 
1500 mg’s defined as high dose and above 1500 
mg’s defined as ultra-high dose.  
Looking at other psychotropic drugs prescription, the 
majority (65%) were also prescribed anticholinergic 
(benzhexol or benztropine). Nearly half were on a 
mood stabilizer (43%) of which lithium, is known to 
have cardiovascular side-effects and was given in 8% 
of the subjects only. Majority of them were 
prescribed concomitant antiepileptic mood stabilizer 
(sodium valproate). About a third were given SSRI 
(32%) and of that only one patient received 
escitalopram, which is also known to have dose-
related effect on QT, particularly in the elderly 
population. Amongst the non-psychotropic drugs, 
anti-lipid drugs topped the list (46%) followed by 
antihypertensives (27%) and anti-hyperglycaemic 
(22%) drugs. Only a quarter had any ECG done in 
the preceding 12 months. 
None of the 37 patients recruited for this study had 
single antipsychotic high dose i.e. above BNF 
recommended limits. All of them had a combination 
of least 2 antipsychotics of which 46 percent were on 
2 and 3 antipsychotics combination respectively. 
None of them noted to have significant electrolyte 
abnormalities that warranted further intervention.  
Rate abnormality was detected (below 60 and above 
100 Bpm) in 8 patients (22%) and of that almost all, 
excepting one, had bradycardia (<60 Bpm). Of those 
with rate abnormality, 75% are Chinese representing 
closely the total cohort but males were slightly 
overrepresented (75%). Comparing to the total cohort 
their age range showed slightly older age group 
individuals between 48 and 65 with a mean age of 
56. Other factors such as number of antipsychotics 
used, the total dose of antipsychotics (high/ultra-high 
doses), number of cardiovascular risk factors all did 
not show any significant impact on rate abnormality 
(Table 2). 
Table 2. Relationship between rate abnormality, dosage, number of antipsychotic and cardiovascular risk 
factors. 
Impact on Heart Rate 
Rate of abnormality 
Normal  
  N (%) 
Abnormal  
  N (%) 
p-value 
  Dosage of antipsychotics 
High dose (1000-1500 mgs CPZ equivalent) 26 (78.8) 7 (21.2) 1.00
b 
Ultra-high dose (>1500 mgs) 3 (75.0) 1 (25)   
  Number of antipsychotics 
less than 3 (<3) antipsychotics 14 (87.5) 2 (12.5) 0.423
b 
3 or more antipsychotics 15 (71.4) 6 (28.6)   
  Cardiovascular risk factors 
less than 3  17 (81.0) 4 (19) 0.705
b 
3 or more  12 (75) 4 (25)   
Note: Fisher exact testb 
PR interval abnormality identified in 2 patients 
(5.4%), shorter PR with sinus rhythm in one, whereas 
the other noted to be prolonged (1st Degree Heart 
Block) with bradycardia. QRS duration was noted to 
be normal in all and only 3 patients (8%) had axis 
deviation (2 left axis and 1 right axis deviation).  
QTc Prolongation was identified in 15 patients (40%) 
by Machine reading but when manually corrected, 
QTc interval normalized in three patients, thereby 
reducing QTc abnormality frequency to 12 patients 
(32%). Of these, 67% are males and 75% are of 
Chinese origin. Their age ranged between 28 and 65 
with a mean age of 47. Age, ethnicity, and gender 
closely represented the total cohort (Table 1). Slight 
QTc prolongation was detected in a male as young as 
28 and female as young as 39. The 28 years old male 
was on Clozapine and risperidone combination with 
QTc reading of machine and manual as 458ms) and 
the 39 years old female was on sulpiride, olanzapine 
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and zuclopenthixol Combination with the machine 
reading of QTc was 498 whilst manually read it 
nearly normalized to only 461 ms). In 8 (22%) 
patients, there was more than the 20 seconds 
difference in QTc interval between machine reading 
and manual reading. ST segment abnormality and T 
wave abnormality was identified in only one patient 
each respectively. A number of antipsychotics used, 
the total dose of antipsychotics used did not show 
significant impact on QTc abnormality (Table 3). 
Whereas the number of cardiovascular risk factors 
made a difference. Those with 3 or more 
cardiovascular risk factors were significantly 
associated with risk of having prolonged QTc. 9 out 
of 16 (56%) with 3 or more cardio-vascular risk 
factor had QTc prolongation whereas only 3 out of 
21 (14.2%) with less than 3 cardiovascular risk 
factors had QTc prolongation.  
Table 3. Relationship between QTc Prolongation, dosage, number of antipsychotic and cardiovascular risk 
factors. 
Impact on QTc 
Normal QTc  
        N (%) 
Prolonged QTc 
         N (%) 
p-value 
  Dosage of antipsychotics  
High dose (between 1000-1500 CPZ equivalent) 22 (66.7) 11 (33.3) 1.00
b 
Ultra-high dose 3 (75.0) 1 (25.0)   
  Number of antipsychotics 
less than 3 (<3) antipsychotics 9 (56.3) 7 (43.8) 0.199
a 
3 or more antipsychotics 16 (76.2) 5 (23.8)   
  Cardiovascular risk factors 
less than 3  18 (85.7) 3 (14.2) 0.007
a 
3 or more  7 (43.8) 9 (56.3)   
Note: Chi-square testa, Fisher exact testb 
 
Only one patient, 65 years old Chinese female is 
noted to have both QTc prolongation (485) and also 
tachycardia (102). Independent rate abnormality was 
noted in the other 7 subjects with bradycardia and 
Independent QTc prolongation abnormality was 
noted in the other 11 subjects. 
Amongst the antipsychotic medications, being only 
on the typical or atypical or mixed group did not 
make any influence on QTc Prolongation (Table 4). 
Having said that the vast majority was on 
combinations of typicals and atypicals (83%). Only 2 
patients had all high doses from atypical 
combinations and 4 had only typical combinations.  
Table 4. Relationship between QT-Corrected interval and with individual antipsychotic or other co-
prescribed medications. 
  QT-Corrected interval (prolonged QTc interval Manual) 
  No Yes 
 
  N (%) N (%) p-value 
Flupenthixol deport   
Typical 2 (50) 2 (50) 0.069a 
Atypical 0 (0) 2 (100) 
 
Flupenthixol deport 
 
No 8 (50%) 8 (50%) 0.046 
Yes 17 (81%) 4 (19%) 
 
Risperidone 
 
No 15 (68.2%) 7 (31.8%) 0.599 
Yes 10 (66.7%) 5 (33.3%) 
 
Quetiapine 
 
No 15 (62.5%) 9 (37.5%) 0.303 
Yes 10 (76.9%) 3 (23.1%) 
 
Haloperidol 
 
No 16 (61.5%) 10 (38.5%) 0.209 
Yes 9 (81.8%) 2 (18.2%) 
 
Chlorpromazine 
 
No 22 (75.9%) 7 (24.1%) 0.055 
Yes 3 (37.5%) 5 (62.5%) 
 
Zuclopenthixol depot 
 
No 20 (69%) 9 (31%) 0.52 
Yes 5 (62.5%) 3 (375%) 
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Olanzapine 
 
No 22 (68.6) 10 (31.3) 1.00b 
Yes  3 (60) 2 (40) 
 
Other Co-prescribed medications 
Mood stabilizer 
   
No 14 (66.7%) 7 (33.3%) 0.893 
Yes 11 (68.8%) 5 (31.3%) 
 
Anticholinergics 
 
No 7 (53.8%) 6 (46.2%) 0.189 
Yes 18 (75%) 6 (25%) 
 
Antihistamines 
 
No 17 (60.7%) 11 (39.3%) 0.121 
Yes 8 (88.9%0 3 (11.1%) 
 
Beta blockers 
 
No 20 (62.5%) 12 (37.5%) 
 
Yes 5 (100.0%) 0 (0%) 0.122 
Antihypertensive 
 
No 19 (70.4%) 8 (29.6%) 0.412 
Yes 6 (60.0%) 4 (40%) 
 
Note: Chi-square testa, Fisher exact testb 
 
The most commonly dispensed antipsychotics 
(flupenthixol decanoate 57%, risperidone 41%, 
quetiapine 35%, haloperidol 22%, 
chlorpromazine22%, zuclopenthixol Decanoate 
22% and olanzapine 13%) were individually 
compared against other antipsychotic as a group 
(Table 4). None of the above showed significant 
impact on QTc interval. Flupenthixol decanoate 
showed negative association compared to having 
other antipsychotics. Authors would like to remind 
that none of the patients were on Mono 
antipsychotic therapy.  
Nearly half had also mood stabilizers prescribed 
and two third of them had anticholinergics. None of 
the co-prescribed medications, including others 
such as anticholinergics, antihistamines, mood 
stabilizers, beta-blockers, and antihypertensives 
had any significant impact on the QTc interval 
results (Table 4).  
Discussion 
Our study focused on high dose antipsychotics and 
also excluded potential confounders such as drugs 
with known QT prolongation effects 
(antiarrhythmics, tricyclics and certain 
antihistamines) and electrolyte abnormalities. In our 
study, only a quarter of the patients on high-dose 
antipsychotics received ECG in the last 12 months. 
This is consistent with previous studies that ECG 
monitoring was inadequate in patients receiving 
antipsychotics. Our study has been the first such 
study in Singapore with a focus on high-dose 
antipsychotic. Apart from looking into ECG 
abnormalities, this study looked at the polypharmacy 
of patients on high dose antipsychotics, whilst the 
majority of the individuals (92%) had combinations 
of 2 or 3 antipsychotics for treatment-resistant cases; 
combinations of more than 3 antipsychotics were 
required in a small proportion (8%) of study subjects. 
This finding is noteworthy too as sometimes 
clinicians erroneously argue that antipsychotic 
polypharmacy reduces the total amount of 
antipsychotic medication.   
Our resident physician calculated QT interval 
manually and then used Bazett’s Formula for rate 
correction and thereby reduced QTc abnormality 
from 40% in machine reading to 32% in manual 
reading. Clinicians are dependent on ECG machine 
interpretations, particularly in psychiatric specialist 
clinics. British Heart Foundation advises that errors 
are common with ECG machines and interpretation 
should not be accepted without Visual inspection 
[18]. The error in calculating QT interval could be 
explained by difficulties in determining the endpoint 
of T wave like the back slope of the T-wave can trail 
off and look rather inconclusive [19,20]. Experts 
usually use 2 best leads that can determine the most 
distinct end points of T wave to calculate QT interval 
and then apply Bazett’s formula for rate correction. 
This has been applied by our resident physician in 
this study. Whenever the machine reading was off 
from the manual reading, the machine tended to 
overestimate the QT interval rather than the other 
way around. Whilst QTc prolongation is a risk factor, 
our patients possibly required such high dose 
medication due to lack of response to usual dose 
mono therapy approaches. Therefore, prudent risk-
benefit analysis is essential before deciding to change 
the antipsychotic drug regime that has been keeping 
the individual well in terms of psychopathology. 
Manual checking of QT interval and rate correction 
plays a significant part in preventing unnecessary 
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medication changes which could cause a detrimental 
relapse of their psychiatric condition.  
The main limitation of the study was the small 
sample size which effectively limits the comparison 
between antipsychotic medications and their QTc 
and rate abnormality. Nevertheless, the authors tried 
to study the risk profiling of this group of patients 
comprehensively including ruling out electrolyte’s 
abnormality. The authors also tried to explore the 
impact of co-prescribed medication such as 
anticholinergics, antihistamines, mood stabilizers and 
also antihypertensives on QTc interval. Another 
limitation to this study has been the lack of control 
groups, such as comparing against similar patient 
profiles but maintained on normal doses.  
This study whilst further confirming the previous 
findings such as elevated risk in those with pre-
existing cardiovascular risk factors, also noted that 
males as young as 28 and females as young as 39 had 
QTc prolongation, necessitating the urgent need to 
ensure compliance with ECG monitoring in all those 
with high dose antipsychotics.  
On manual reading of ECG, QTc prolongation was 
detected in 12 patients. Of which 9 patients had a 
slight increase in manual reading (<10 ms increase), 
3 patients had more than 10 ms prolongation of 
which only one patient had more than 20 ms 
increase. If clinicians only take machine reading into 
account, the QTc prolongation is overestimated. The 
frequency of having more than 10 ms prolongation 
was noted in 8 patients by machine reading and it 
reduced to only 3 patients when manually read. 
Interestingly one female patient had QTcB as 530 ms 
in machine reading of QT interval but normalized to 
426 ms when manual reading of QT interval was 
done along with the use of same Bazett’s formula for 
rate correction. Another female patient had 473 ms in 
machine reading which normalized to 436 ms when 
manually red by our resident physician. This study 
highlighted that clinically significant ECG 
abnormalities frequency is reduced when the QTc 
interval was properly calculated manually by experts 
or trained personnel even in our high dose 
antipsychotic patients. We do acknowledge that the 
study sample size remains as a potentially limiting 
factor for our study. Authors would like to highlight 
a study done in a much bigger population of 725 
patients pointed out that antipsychotic dose mediated 
the association between polypharmacy and corrected 
QT interval [20].  
It is also important to highlight the role of the genetic 
variation as the modulating factor for QT interval 
prolongation in psychopharmacological treatment 
and therefore contribute valuable information 
towards personalized medicine in the future [21]. 
This study covered all psychotropic medications that 
are known to prolong QTc and identified in its 
secondary analysis some genes (ABCB1, NOS1AP, 
and KCNH2) may play a role in QTc 
duration/prolongation during treatment with 
psychotropic drugs.  
Beyond QTc interval other related sub-parameters 
such as Peak to end of T Wave (Tp-e) and QT 
dispersion are also studied to understand the impact 
of Psychotropics and ventricular repolarisation [22]. 
The components of QTc such as Tp-e and Tp-e/QT 
ratio might be superior biomarkers because they 
better reflect increased transmural dispersion of 
ventricular myocyte repolarisation which can lead to 
TdP. One recent study highlighted that given the 
observed variability in QTc, Tpe, and Tpe/QT ratio, 
24-hour ECG recordings warranted to provide an 
accurate assessment of the risk of TdP rather than 
just relying on rate corrected QT interval to capture 
the risk of TdP [23].  
Recommended Guidelines for High Dose-
Antipsychotics 
1. Ensure high dose is clinically required and 
periodic review of such at least on annual basis 
during the already established Annual Review 
Clinic  
2. Before Initiation:  
a. Cardio-Vascular risk profiling (Past history of 
CVS disease, Family History of CVS disease, 
DM, HTN, Lipids, Smoking, Absence of 
Exercise and Obesity) 
b. Screening for concurrent medication that 
enhances QT prolongation risk 
c. Baseline ECG 
3. After initiation: 
a. Perform follow up ECG, repeating on an 
annual basis, early if further dose increase is 
required for clinical reasons  
b. Clinician involved in such prescribing to be 
taught to manually evaluate QTc interval 
alongside regular refresher training at the 
periodic interval to reduce false alarms and 
false negatives  
4. Early intervention for QTc interval abnormality 
such as dose reduction and to seek cardiologist 
opinion where necessary  
5. Periodic auditing of compliance to such 
recommendation could increase clinical utility  
Conclusion 
Our study found that ECG monitoring remains 
inadequate in patients with Schizophrenia, even in 
patients receiving a high dose of antipsychotics. 
Interestingly the frequency of significant QTc 
prolongation abnormality reduced drastically when 
manual reading and rate correction was done by 
experts and trained personnel. In our study, ECG 
manual reading picked up QTc prolongation in 12 
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patients (32%) of the total sample but that reduced to 
just only 3 if we were to only include patients with 
more than 10ms increase from recommended upper 
limit. Oftentimes, high doses of psychotropics are 
justified as a clinical necessity. The discrepancy 
between machine and manual reading of QTc 
highlighted that clinician-guided reading can avoid 
false alarms and prevent unnecessary dose down-
titration that could potentially increase the risk of 
relapse. Therefore, the authors recommend clinical 
guidelines (as listed below) be enforced and overseen 
by a clinical pharmacist to ensure adequate and 
appropriate (clinician-guided QTc interval) 
monitoring for patients on antipsychotic medications 
and in particular for high dose prescriptions. 
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